Home MarketDivi's Laboratories Ltd.

Divi's Laboratories Ltd. Stock Info: As on 2017-11-20 15:59:54

Nse

1047.55

26.90(2.64%)
Change%
52 Week Range
532.65
29.00
1,197.45
21.00
Open1,017.50
Day's Range918.59 - 1,122.72
Value Traded (in ₹ Cr.) 161.15

Bse

1043.25

24.95(2.45%)
Change %
52 Week Range
533.10
29.00
1,193.80
21.00
Open1,028.95
Day's Range916.47 - 1,120.13
Value Traded (in ₹ Cr.) 8.72

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 50,000.00 0.02%
IndianPromoters 138,181,232.00 52.05%
Mutual Funds/UTI 42,084,185.00 15.85%
FII 43,167,897.00 16.26%
Employee 0.00 0.00%
Public 24,097,096.00 9.08%
Government 0.00 0.00%
Others 16,986,579.00 6.40%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 7.03
Basic EPS (Rs.) 41.73
Cash EPS 46.17
BVPerShare Excl 163.87
Operating Revenue 140.18
PBDITPerShare 56.21
Dividend 10.00
NPPerShare 41.73
Current Ratio 6.04
Quick Ratio 3.79
PriceToBV 6.01
Earnings 0.04
PBDIT Margin 40.10
PBT Margin 36.86
NP Margin 29.76
Return On Assets 22.03
Retention Ratios 76.03
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 3,815.73
Total Expenses 2,443.89
EBITDA 1,492.26
PBT 1,371.84
PAT 1,107.69
Net Income 1,107.69
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,980.80
Total Expenses 1,287.13
EBITDA 634.56
PBT 691.91
PAT 568.78
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 53.09
Net worth 4,350.14
Investments 805.35
Total Liability 5,027.50
Total debt 41.89
Net block 1,702.55
Total Assets 5,027.50
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 53.09
Net worth 4,100.87
Investments 662.79
Total Liability 4,761.28
Total debt 36.68
Net block 1,590.62
Total Assets 4,761.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

536.5 532.4 0.77
520.4537

Abbott India Ltd.

4944.85 4948.2 -0.07
45955413.4

Ajanta Pharma Ltd.

1335.2 1273.4 4.85
1186.951279

Albert David Ltd.

290.05 292 -0.67
275.1297.15

Alembic Ltd.

39.35 39.3 0.13
38.540.45

Alembic Pharmaceuticals Ltd.

515.4 516.1 -0.14
511.2532.2

Alkem Laboratories Ltd.

1977.6 1974.85 0.14
19102019.6
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

50.75 46.45 9.26
45.562.15

Aarti Drugs Ltd.

525.5 532.85 -1.38
520.05536.95

Aayush Food & Herbs Ltd.

48.95 44.6 9.75
39.1544.6

Abbott India Ltd.

4998 4942 1.13
46005401.3

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 1,032.40
Cash from investing activities -413.43
Cash from financing activities -624.14
Net change in cash -5.17

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Reliance Equity Opportunities Fund 4.40%
SBI Magnum Balanced Fund 2.33%
SBI Blue Chip Fund 1.45%
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.97%
Reliance Pharma Fund 10.46%
Reliance Top 200 Fund 3.07%

L&T Dynamic Equity Fund - Regular Plan: change in investment factsheets for Oct

L&T Dynamic Equity Fund - Regular Plan has announced change in investment factsheets and fund flash for the month ended October 31, 2017. As on Oct 31, 2017, the total size of the Fund was Rs 473.65 crores, compared with Rs 471.48 crores in the last month. The Fund's NAV per unit was Rs 22.45 for Growth, while 52-Week High and Low ranges were Rs 22.50 and Rs 20.00 respectively. The Equity - Hybrid fund with Growth plan was launched on Jan 17, 2011 and managed by Fund Managers Soumendra Nath Lahiri, Jalpan Shah, Praveen Ayathan. The top five companies based on a percentage of total holdings were IDFC Limited (34.40 Cr.), Balrampur Chini Mills Limited (18.18 Cr.), Just dial Limited (15.15 Cr.), Kotak Mahindra Bank Limited (11.78 Cr.) and Bajaj Finance Limited (11.70 Cr.). L&T Dynamic Equity Fund - Regular Plan is promoted by L&T Mutual Fund and managed by L&T Investment Management Ltd..

20-11-2017 11:30

Moody's assigns Baa2 ratings to RIL's proposed USD bonds

Moody's Investors Service, a global rating agency, has assigned a Baa2 rating to the proposed USD-denominated senior unsecured bonds of Reliance Industries Limited (RIL). The outlook on the rating is stable. The bond proceeds will be used for refinancing. The proposed bond will rank pari passu with all of RIL's other existing and future unsecured and unsubordinated obligations. RIL's Baa2 ratings reflects the company's strong ability to generate operating cash flows, with annual 1EBITDA exceeding $10 billion from its large-scale integrated refining and petrochemical operations — which generate strong margins — and the company's nascent but growing digital services business, says Vikas Halan, Moody's Vice President and Senior Credit Officer. The Baa2 rating also incorporates the increase in RIL's business risk because of its growing digital services segment and our expectation that the high cash outflow for capital spending will keep its free cash flow negative over at least next 18 months adds Halan, who is also Moody's Lead Analyst for RIL. Even though RIL's projects in the refining and petrochemical segments are coming to an end, the cash outflow for capital spending will remain high as payments to creditors for past capital expenditure are made over the next 12-18 months. Such payments along with additional capital spending in the digital services business will constrain any reduction in net borrowings until fiscal 2019 ending March 2019. The company's digital services business -- Jio — reported positive EBITDA for the quarter ended 30 September 2017. Jio has significant potential to increase its EBITDA over the next 2-3 years, as it adds more subscribers and stabilizes average revenue per user at a higher level. However, the company's evolving strategy, the intense competition, and the ongoing consolidation in the Indian telecommunications industry, lowers Moody's visibility on the extent of the EBITDA improvement for this segment. The outlook on the ratings is stable, reflecting Moody's expectation that the company's earnings will continue to improve over the next 12-18 months across all its business segments, such that its credit metrics will become more appropriately positioned for its ratings, despite negative free cash flows.

20-11-2017 11:18

Coal dispatches from CIL to power sector rise 18% to 39.9 MT in Oct

Coal dispatches from state-run miner Coal India Ltd (CIL) to power sector improved by 18 per cent to 39.9 million tonnes (MT) in October, official data showed. The power ministry earlier this month had also stated that coal stocks at power plants were much better and dry fuel inventories had started building up at the plants. Coal India had supplied 33.8 MT of dry fuel to power producers in October 2016. The dispatches by the world's largest coal miner rose by 9.6 per cent to 248.9 MT in the April-October period of this financial year over 227 MT in the year-ago period. The supply of coal by Singareni Collieries Company Ltd (SCCL), a state-owned coal mining company, also registered an increase of five per cent to 4.2 MT, over 4 MT in the same month of the previous financial year. Power Secretary Ajay Kumar Bhalla had earlier in the month said that the number of plants facing acute coal shortage had come down to 12-13. The coal ministry earlier had blamed power producers for low stocks of dry fuel at their plants. Karnataka Chief Minister Siddaramaiah had last month asked the Centre to ensure adequate supply of coal and early allocation of a coal block situated in Odisha to meet the severe fuel shortage being faced by power units in his state. Rajasthan Urja Vikas Nigam in September had said that power generation at thermal power stations reduced by 2,700 Mw due to shortage of coal, forcing it to resort to load shedding in the state. Meanwhile, shares of Coal India were trading at Rs 276.45 apiece, up 1.32 per cent from the previous close at 11:14 hours on BSE.

20-11-2017 11:10

Divi's Laboratories Vizag unit receives USFDA EIR with six observations

Drug firm Divi's Laboratories on Saturday said it has received an establishment inspection report (EIR) from the US health regulator for its unit in Visakhapatnam. Divi's Laboratories unit-II at Visakhapatnam was inspected by the USFDA in September 2017 wherein a form-483 was issued with six observations. We have now received an Establishment Inspection Report (EIR) from US-FDA for our Unit-II, as the closure of audit by FDA, the company said in a BSE filing. The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA inspection when the agency determines the inspection to be closed. Meanwhile, shares of the company were trading at Rs 1030.95 apiece, up 1.24 per cent from the previous close at 11:08 hours on BSE.

20-11-2017 11:02

Cipla bags final approval for Decitabine Injection

Cipla Ltd, a global pharmaceutical company has said that it has received final approval for its Abbreviated New Drug Application (ANDA) for Decitabine Injection 50 mg single-use sterile vial from the United States Food and Drug Administration (US FDA) to market generic version of Otsuka America Pharmaceutical Inc.’s Dacogen®. Cipla’s Decitabine Injection 50 mg/vial is AP-rated and is generic equivalent of Otsuka America Pharmaceutical Inc.’s, Dacogen®. It is indicated for treatment of patients with myelodysplastic syndromes (MDS). The product is available for shipping immediately. Dacogen® and its generic equivalents had U.S. sales of approximately $180M for the 12-month period ending September 2017, as reported by IMS Health. Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. Meanwhile, shares of the company were trading at Rs 601.05 apiece, down 1.25 per cent from the previous close at 11:05 hours on BSE.

20-11-2017 11:01

Divi's Laboratories Vizag unit receives USFDA EIR with six observations

Drug firm Divi's Laboratories on Saturday said it has received an establishment inspection report (EIR) from the US health regulator for its unit in Visakhapatnam. Divi's Laboratories unit-II at Visakhapatnam was inspected by the USFDA in September 2017 wherein a form-483 was issued with six observations. We have now received an Establishment Inspection Report (EIR) from US-FDA for our Unit-II, as the closure of audit by FDA, the company said in a BSE filing. The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA inspection when the agency determines the inspection to be closed. Meanwhile, shares of the company were trading at Rs 1030.95 apiece, up 1.24 per cent from the previous close at 11:08 hours on BSE.

20-Nov-2017 11:02 AM

Divi's Lab - Updates

Divi''s Laboratories Limited has informed the Exchange regarding ''We had earlier informed the Exchanges that the company?s Unit-II at Visakhapatnam was inspected by US-FDA in September, 2017 wherein a Form-483 was issued with 6 observations.In this regard, we wish to inform you that we have now received an Establishment Inspection Report (EIR) from US-FDA for our Unit-II, as closure of audit by FDA.''.

18-Nov-2017 12:05 PM

USFDA lifts import alert on Divi's Labs Vizag unit

Drug firm Divi’s Laboratories today said the US health regulator has lifted import alert imposed on its unit at Visakhapatnam. Last week, the company in a regulatory filing had said the US Food and Drug Administration (USFDA) had “closed out” a warning letter issued to the unit in Visakhapatnam following evaluation of corrective actions taken by the company at the plant. “The FDA’s website has now been updated on November 14, 2017, and the import alert 66-40 on the company’s unit-II has been removed,” the company said in a BSE filing. The USFDA in March had issued import alert under clauses 99-32 and 66-40 and a warning letter later for the Visakhapatnam facility for non-compliance of good manufacturing practices (GMP) norms, the company had informed bourses earlier. The company in July announced that the USFDA had moved to lift Import Alert 99-32 imposed on the unit. As per the USFDA, an import alert under 66-40 entails “detention without physical examination” of drugs from firms which have not met drug GMPs while alert under 99-32 is issued to “firms refusing FDA foreign establishment inspection“. Meanwhile, shares of the company were trading at Rs 1029.50 apiece, up 0.50 per cent from the previous close at 12:02 hours on BSE.

15-Nov-2017 11:55 AM

Divi's Lab - Updates

We had earlier informed the Exchanges vide our letter of 2nd November, 2017 that the US-FDA will be lifting the Import Alert 66-40 imposed on the company's Unit-II at Visakhapatnam.

The FDA's website has now been updated on 14th November, 2017 and the Import Alert 66-40 on the company's Unit-II has been removed

15-Nov-2017 08:45 AM

Divi's Lab - Updates

Divi''s Laboratories Limited has informed the Exchange regarding ''We had earlier informed the Exchanges vide our letter of 2nd November, 2017 that the US-FDA will be lifting the Import Alert 66-40 imposed on the company?s Unit-II at Visakhapatnam.The FDA?s website has now been updated on 14th November, 2017 and the Import Alert 66-40 on the company?s Unit-II has been removed''.

15-Nov-2017 08:44 AM

Divi's Lab - Updates

We had earlier informed the Exchanges vide our letter of 2nd November, 2017 that the US-FDA will be lifting the Import Alert 66-40 imposed on the company's Unit-II at Visakhapatnam.

The FDA's website has now been updated on 14th November, 2017 and the Import Alert 66-40 on the company's Unit-II has been removed

15-Nov-2017 08:45 AM

Divi's Lab - Updates

Further to our letter dated 2nd November, 2017, Divi's Laboratories has been informed by the US-FDA that the Agency has completed evaluation of the Company's corrective actions in response to FDA's Warning Letter: 320-17-34 dated April 13, 2017. We also note from the update on FDA's website that they have closed-out the warning letter.

10-Nov-2017 09:05 AM

Divi's Lab - Updates

Divi's Laboratories has been informed by the US-FDA that it will be lifting the Import Alert 66-40 and moving to close out the Warning letter issued to the company's Unit-II at Visakhapatnam.

02-Nov-2017 08:37 AM

Corporate Details

About Management

Milestones: 1990 -Divis Research Center (DRC) established. 1991-1993 -DRC successfully develops several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. 1994 -Divis Research Center changes its name to Divis Laboratories Limited to reflect its growing area of operations and its plans to enter the manufacturing sector in the following year. 1995 -Manufacturing Facility (Unit-1) at Choutuppal near Hyderabad starts operations. 1997 -SGS-Yarsley of U.K certifies Divis Laboratories as ISO-9002 compliant. 1999 -European Directorate gives a "Certificate of Suitability" (CoS) for Naproxen produced at Divis Laboratories. 2000 -US-FDA inspects Divis Laboratories successfully SGS-Yarsley of U.K awards Divis the ISO 9001 Certification SGS International AG of Switzerland awards Divis the ISO-14001 Certification (for its efficient Environment Management Systems). 2001 -BVQI of London awards Divis the OHSAS-18001 Certification (for its Occupational Health and Safety Management Systems). 2002 -Divis commences the setting up of its 2nd Manufacturing Facility (Unit-2) at Chippada near Visakhapatnam. 2003 -Divis opens a new research center christened `DRC-Vizag' for fundamental research in selected niche business core segments. -Went for IPO and listed on stock exchanges BSE, NSE and HSE. -Divi's Laboratorie receives Certificate of Substantiability from the council of Europe -Appointed Mr A Narendra as Company Secretary & Compliance Officer of the company (in place of outgoing Company Secretary Mr P Sudarshan) who has joined the organization. 2004 - Divi'S Laboratories Limited has informed that the manufacturing facility of Divi's Labs at Choutuppal near Hyderabad was successfully inspected by US-FDA in May 2004. -US-FDA inspects the Choutuppal (Unit-1) for a second time. No 483. 2006 -Delists equity shares form The Hyderabad Stock Exchange Ltd (HSE), Hyderabad with effect from March 29, 2006. -US-FDA inspects the Visakhapatnam(Unit-2) for the first time. 2007 - The Company has splits its face value from Rs10/- to Rs2/-. 2008 -Third US-FDA inspection for Choutuppal(Unit-1). 2009 - Certified and Awarded for "Best Green Belt Development" - SURAKSHA PURASKAR for the year 2008 - ISO 14001: 2004 (Re-Certification) "Environment Management System" -Divi's Laboratories has given the Bonus in the Ratio of 1:1 2010 - Divis Lab - Setting up of a new Unit in SEZ at Visakhapatnam. - The Company has recommended a dividend of 300% i.e. Rs. 6/- per equity share of Rs. 2/- face value for the year ended March 31, 2010. 2011 - Divi’s Laboratories surged 3.5 per cent in early morning trade on Bombay Stock Exchange on November 2, 2011, after the announcement of healthy growth in Q2 numbers on November 1, 2011, after trading hours. - Shares of the company after opening higher at Rs 765 from previous close of Rs 759.20, rose to hit a high of Rs 785.40 on BSE, reflecting the gain of 3.5 per cent. At 11:05 AM, the stock was trading at Rs 772.85 on Bombay Stock Exchange. 2012 - Divis Laboratories Ltd has informed BSE that the Board of Directors through Circular resolution dated March 07, 2012 has decided to seek shareholders approval by postal ballot for Re-appointment and revision in remuneration of Mr. Madhusudana Rao Divi as Director-Projects of the Company. - The Company Re-appointment and revision in remuneration of Mr. Kiran S. Divi Director & President- Operations of the Company. - Enhancement of remuneration of Dr. Murali K. Divi, Chairman & Managing Director of the Company. - Enhancement of remuneration of Mr. N. V. Ramana, Executive Director of the Company. 2013 -Divis Laboratories Ltd. has recommended a dividend of 750% i.e. Rs. 15/- per equity share of Rs. 2/- face value for the year ended March 31, 2013. 2014 -Divis Laboratories Ltd. has recommended a dividend of 1000% i.e. Rs. 20/- per equity shares of Rs. 2/- face value for the year ended March 31, 2014. 2015 -Divis Laboratories Ltd has approved to give bonus shares on the eve of 25th year of formation of the Company, in the ratio of 1:1. 2016 -Divis Labs unit-2 at Chippada successfully inspected by USFDA

Registered Office

DSN SEZ Unit : Chippada Village, Bheemunipatnam Mandal,

,,,      ,

Registrar Details

Karvy Computershare Private Ltd.